Screening Libraries

Product Data Sheet

FR122047

Cat. No.: HY-103386 CAS No.: 130717-51-0 Molecular Formula: $C_{23}H_{26}CIN_3O_3S$

Molecular Weight: 459.99 COX Target:

Pathway: Immunology/Inflammation

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (217.40 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1740 mL	10.8698 mL	21.7396 mL
	5 mM	0.4348 mL	2.1740 mL	4.3479 mL
	10 mM	0.2174 mL	1.0870 mL	2.1740 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.43 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.43 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	FR122047 (hydrochloride) is a selective and oral active inhibitor of COX-1 with an IC ₅₀ of 28 nM. FR122047 hydrochloride has antiplatelet, analgesic and anti-inflammatory effects in vivo $^{[1][2][3]}$.
IC ₅₀ & Target	COX-1 28 nM (IC ₅₀)

REFERENCES

[1]. Dohi M, et al. The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur J Pharmacol. 1993 Oct 19;243(2):179-84.

[2]. Ochi T, Motoyama Y, Goto T. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol. 2000 Mar

10;391(1-2):49-54.				
[3]. Ochi T, Goto T. Differenti	al effect of FR122047, a select	ive cyclo-oxygenase-1 inhibitor, i	n rat chronic models of arthritis. Br J P	harmacol. 2002 Feb;135(3):782-8.
	Courtieur Due doort le co		andiantamatications Farmananah	usa sulu
	Tel: 609-228-6898	Fax: 609-228-5909	nedical applications. For research E-mail: tech@MedChemExp	
			nouth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com